Nasal spray shows promise against suicidal thoughts – but who benefits most?
NCT ID NCT07199179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a nasal spray called esketamine can quickly reduce suicidal thoughts in people with severe depression. Researchers want to find out if symptoms like loss of pleasure (anhedonia) or emotional pain can predict who will benefit most. The study re-analyzes data from two earlier trials involving 456 patients. It does not test a new treatment but aims to better understand how esketamine works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Montpellier
Montpellier, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain zapping gets personal: a new approach to treating depression and anxiety
- Faith-Based therapy aims to heal trauma in young women
- Can we predict who returns to work after stress treatment?
- Rewiring the brain: could neurofeedback break the loop of suicidal thoughts?
- Can a longer hospital stay save lives? a nationwide study investigates
- Brain zaps tuned to your wiring: a new hope for depression?